Skip to main content
Premium Trial:

Request an Annual Quote

ABRF, Max Planck, HUPO, Boehringer Ingelheim, Ablynx, BaroFold, Millipore, J&J

Premium
ABRF Extends Standards Research Deadline, Seeks Researchers
 
The Association of Biomolecular Resource Facilities has extended the deadline for submissions for the Proteomics Standards Research Group study sample to Jan. 29.
 
The organization asks researcher to submit data by filing out the survey here. Supporting files should be uploaded here.
 
ABRF recommends that participants use SwissProt as the database of reference for protein identifications. It also asks that participants submit any data, even incomplete information, as it is interested in unsuccessful analyses as well as successful ones. All results will be compiled anonymously, ABRF said.
 
The group is also seeking individuals interested in serving on the Proteomics Research Group as well as the Proteomcs Standards Research Group. Individuals interested in joining the PRG should contact Arnie Falick at [email protected], and those interested in the PSRG should contact Mary Ann Gawinowicz at [email protected], and those interested in the PSRG should contact Mary Ann Gawinowicz at
 

 
Max Planck Takes Delivery of Synapt HDMS
 
Waters announced last week that the Max Planck Institute has taken delivery of the Waters Synapt High Definition system to study the role of proteins in neurodegenerative diseases.
 
Ulrich Hartl will direct the research and Manajit Hayer-Hartl will be the principal investigator. They will focus on the mechanisms by which molecular chaperones mediate protein folding and inhibit misfolding in neurodegenerative diseases.
 
Waters introduced the instrument at ASMS in June.
 

 
From HUPO for Your Review, Please
 
The Human Proteome Organization is seeking comment on manuscripts currently being offered for community consultation by Nature Biotechnology. Four manuscripts from the HUPO Proteomics Standards Initiative and three with PSI participation are being offered by the journal for consideration. Two more manuscripts are expected soon.
 
The manuscripts can be reviewed here and comments can be sent to [email protected]
 

 
Boehringer Ingelheim, Ablynx to Develop Alzheimer’s Treatments
 
Boehringer Ingelheim will use Ablynx’s novel class of therapeutic proteins to develop therapies for Alzheimer’s disease, the companies said this week.
 
The worldwide exclusive licensing agreement is worth about $265 million, the companies said, and includes an upfront fee, and milestone and development payments to Ablynx. It will also receive undisclosed royalties based on net sales.
 
Boehringer will start a join research program that will include Ablynx scientists. Under the agreement Boehringer will be solely responsible for the development, manufacture, and commercialization of any products resulting from the collaboration.
 

 
BaroFold Licenses Protein Structure Technology to Pfizer
 
BaroFold announced this week it has granted a multi-site license to Pfizer for its proprietary PreEMT high pressure technology for solubilizing, disaggregating, and refolding proteins.
 
Financial terms of the deal were not disclosed.
 

 
Millipore, J&J’s Janssen Collaborate on Protein Kinase Screening
 
Under an agreement announced this week, the Janssen Pharmaceutica division of Johnson and Johnson Pharmaceutical R&D will use Millipore’s Upstate Kinase Profiler for protein kinase screening.
 
J&JPRD will supply potential kinase inhibitors for kinase selectivity profiling against Millipore’s panel of 252 protein and lipid kinases, the companies said. No other terms of the agreement were disclosed.
 
The panel of kinases assembled represents the largest and most disease-relevant of its kind, Millipore said in a statement. 

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.